Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Ascendis
Pharma
BioMarin touts pipeline asset as potential Voxzogo replacement
Competition is coming for BioMarin’s Voxzogo, but it may be able to answer with a longer-acting version of the drug, which treats a form of dwarfism.
Kevin Dunleavy
Aug 5, 2025 11:30am
Ascendis must wait 3 more months for FDA verdict on TransCon PTH
May 14, 2024 5:36pm
AstraZeneca, BeiGene, Coherus—Fierce Pharma Asia
Dec 1, 2023 8:34am
Pfizer gets EU approval for long-acting human growth hormone
Feb 22, 2022 7:30am
The potential blockbusters still awaiting FDA decisions in 2021
Sep 13, 2021 10:57am
Ascendis' long-acting growth hormone wins FDA blessing
Aug 25, 2021 7:33pm
